Xilio Therapeutics (XLO) Balance Sheet: Assets & Liabilities

Xilio Therapeutics (XLO) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Xilio Therapeutics reported total assets of $154.69M and total liabilities of $119.41M. Shareholders' equity was $35.27M, up 100.4% from $17.60M a year earlier. Total debt stood at $6.95M against $137.53M in cash and short-term investments, a net cash position of $130.58M. That puts debt-to-equity at 0.20, compared with 0.46 a year earlier.

Xilio Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Xilio Therapeutics, Inc. (XLO) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	137.53	55.29	44.70	120.39	198.05	19.24	48.85
Cash & Short-Term Investments	137.53	55.29	44.70	120.39	198.05	19.24	48.85
Accounts Receivable	5.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	7.50	4.94	3.42	4.11	4.46	1.35	2.26
Total Current Assets	145.03	60.23	48.13	124.50	202.52	20.59	51.10
Non-Current Assets
Property, Plant & Equipment (Net)	7.85	9.06	11.07	12.84	13.60	14.06	9.87
Long-Term Investments	1.81	1.78	0.00	1.56	1.55	0.00	0.19
Other Non-Current Assets	1.81	1.78	1.73	1.83	1.95	1.66	1.55
Total Non-Current Assets	9.66	10.84	12.80	14.67	15.54	15.73	11.62
Total Assets	154.69	71.08	60.93	139.17	218.06	36.32	62.72
Current Liabilities
Accounts Payable	3.17	2.57	1.05	3.13	3.14	5.44	2.52
Short-Term Debt	1.34	1.19	3.32	6.67	0.88	2.33	0.00
Current Portion of Long-Term Debt	-	-	3.32	6.67	0.08	2.33	-
Accrued Liabilities	11.74	5.77	5.81	10.33	8.75	13.73	-
Deferred Revenue	40.02	13.52	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	11.74	9.98	0.05	0.08	12.78	13.73	2.69
Total Current Liabilities	56.27	27.26	15.96	21.12	12.78	22.16	5.21
Non-Current Liabilities
Long-Term Debt	5.61	6.95	8.14	3.17	9.63	7.81	18.63
Deferred Tax Liabilities	0.00	0.00	0.00	0.00	3.54	0.00	0.00
Other Non-Current Liabilities	57.53	0.00	0.00	0.05	0.12	0.54	0.37
Total Non-Current Liabilities	63.14	26.22	8.14	12.40	19.85	19.45	19.01
Total Liabilities	119.41	53.48	24.10	33.52	32.63	41.60	24.21
Stockholders' Equity
Common Stock	36.89	0.01	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-418.79	-383.75	-325.51	-249.11	-160.89	-85.09	-29.87
Additional Paid-in Capital	417.17	401.35	362.34	354.75	346.31	1.80	0.34
Shares Outstanding	4.53	3.27	1.97	1.96	27.36	-	-
Total Stockholders' Equity	35.27	17.60	36.83	105.65	185.43	-5.29	38.51
Total Liabilities & Equity	154.69	71.08	60.93	139.17	218.06	36.32	62.72

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xilio Therapeutics Balance Sheet

How much debt does Xilio Therapeutics have?

Xilio Therapeutics had total debt of $6.95M as of Dec 31, 2025, against $137.53M in cash and short-term investments. Its debt-to-equity ratio was 0.20. Total debt was $8.14M a year earlier.

What are Xilio Therapeutics's total assets?

Xilio Therapeutics reported total assets of $154.69M as of Dec 31, 2025, up 117.6% from $71.08M a year earlier. Total liabilities were $119.41M.

What is Xilio Therapeutics's shareholders' equity?

Xilio Therapeutics's shareholders' equity was $35.27M as of Dec 31, 2025, or about $7.79 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition